Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Keiran S.M. Smalley(Moffitt Cancer Center), Katherine L. Nathanson(Translational Therapeutics (United States))
Cited by 97
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
|Cancer Research|2011|546